Clinical Trial Update: CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update on a CD123-targeted CAR-T cell therapy for relapsed/refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD123-targeted CAR-T cell therapy

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Leukemia, Leukemia, Myeloid | Phase 1, Phase 2 | Status: UNKNOWN